Effects of poverty and race on outcomes in acute myeloid leukemia

Margaret M. Byrne, L. Jill Halman, Leonidas Koniaris, Peter A. Cassileth, Joseph D. Rosenblatt, Michael C. Cheung

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objectives: To determine how patient race, ethnicity, and degree of poverty affect treatment and survival for acute myeloid leukemia (AML). Methods: A linked database of the Florida cancer registry and State inpatient and outpatient hospital data for 1998-2002 was queried. Effects of demographic and treatment characteristics on survival were explored using univariate and multivariate analyses methods. Results: A total of 4659 patients with AML were identified. Over 50% of patients with AML were 70 years of age or older. African American (AA) patients were diagnosed at significantly younger ages than were whites (P <0.001). In multivariate analysis, independent predictors of worse survival in AML were aged over 50 (hazard ratios [HRs]: 1.60, 2.15, 3.04, and 3.62 over the decade-cohorts, all P <0.001), AA race (HR: 1.27, P <0.001), being a former or current user of tobacco (HR: 1.13, P = 0.004 and HR: 1.28, P <0.001, respectively), residing in an area with the highest poverty level (HR: 1.15, P = 0.007), and being covered only by Medicaid (HR: 1.23, P = 0.014). No differences in outcomes were observed related to gender or ethnicity. Receipt of chemotherapy was strongly associated with improved survival (HR: 0.59, P <0.001). When only those patients who received and appeared to respond to treatment are included, AAs continued to demonstrate a worse outcome than Whites. Conclusions: AML disproportionately affects the elderly. AA patients and patients from poorer communities with AML have significantly worse survival. Interventions to provide earlier diagnosis in these patients as well as to improve overall outcomes are needed to address these disparities.

Original languageEnglish (US)
Pages (from-to)297-304
Number of pages8
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume34
Issue number3
DOIs
StatePublished - Jun 2011
Externally publishedYes

Fingerprint

Poverty
Acute Myeloid Leukemia
Survival
African Americans
Multivariate Analysis
Medicaid
Tobacco
Registries
Inpatients
Early Diagnosis
Outpatients
Therapeutics
Demography
Databases
Drug Therapy
Neoplasms

Keywords

  • acute myeloid leukemia
  • outcomes
  • race
  • socioeconomic status
  • treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Effects of poverty and race on outcomes in acute myeloid leukemia. / Byrne, Margaret M.; Halman, L. Jill; Koniaris, Leonidas; Cassileth, Peter A.; Rosenblatt, Joseph D.; Cheung, Michael C.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 34, No. 3, 06.2011, p. 297-304.

Research output: Contribution to journalArticle

Byrne, Margaret M. ; Halman, L. Jill ; Koniaris, Leonidas ; Cassileth, Peter A. ; Rosenblatt, Joseph D. ; Cheung, Michael C. / Effects of poverty and race on outcomes in acute myeloid leukemia. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2011 ; Vol. 34, No. 3. pp. 297-304.
@article{2dcc2731aabd4e5588778716df950e75,
title = "Effects of poverty and race on outcomes in acute myeloid leukemia",
abstract = "Objectives: To determine how patient race, ethnicity, and degree of poverty affect treatment and survival for acute myeloid leukemia (AML). Methods: A linked database of the Florida cancer registry and State inpatient and outpatient hospital data for 1998-2002 was queried. Effects of demographic and treatment characteristics on survival were explored using univariate and multivariate analyses methods. Results: A total of 4659 patients with AML were identified. Over 50{\%} of patients with AML were 70 years of age or older. African American (AA) patients were diagnosed at significantly younger ages than were whites (P <0.001). In multivariate analysis, independent predictors of worse survival in AML were aged over 50 (hazard ratios [HRs]: 1.60, 2.15, 3.04, and 3.62 over the decade-cohorts, all P <0.001), AA race (HR: 1.27, P <0.001), being a former or current user of tobacco (HR: 1.13, P = 0.004 and HR: 1.28, P <0.001, respectively), residing in an area with the highest poverty level (HR: 1.15, P = 0.007), and being covered only by Medicaid (HR: 1.23, P = 0.014). No differences in outcomes were observed related to gender or ethnicity. Receipt of chemotherapy was strongly associated with improved survival (HR: 0.59, P <0.001). When only those patients who received and appeared to respond to treatment are included, AAs continued to demonstrate a worse outcome than Whites. Conclusions: AML disproportionately affects the elderly. AA patients and patients from poorer communities with AML have significantly worse survival. Interventions to provide earlier diagnosis in these patients as well as to improve overall outcomes are needed to address these disparities.",
keywords = "acute myeloid leukemia, outcomes, race, socioeconomic status, treatment",
author = "Byrne, {Margaret M.} and Halman, {L. Jill} and Leonidas Koniaris and Cassileth, {Peter A.} and Rosenblatt, {Joseph D.} and Cheung, {Michael C.}",
year = "2011",
month = "6",
doi = "10.1097/COC.0b013e3181dea934",
language = "English (US)",
volume = "34",
pages = "297--304",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effects of poverty and race on outcomes in acute myeloid leukemia

AU - Byrne, Margaret M.

AU - Halman, L. Jill

AU - Koniaris, Leonidas

AU - Cassileth, Peter A.

AU - Rosenblatt, Joseph D.

AU - Cheung, Michael C.

PY - 2011/6

Y1 - 2011/6

N2 - Objectives: To determine how patient race, ethnicity, and degree of poverty affect treatment and survival for acute myeloid leukemia (AML). Methods: A linked database of the Florida cancer registry and State inpatient and outpatient hospital data for 1998-2002 was queried. Effects of demographic and treatment characteristics on survival were explored using univariate and multivariate analyses methods. Results: A total of 4659 patients with AML were identified. Over 50% of patients with AML were 70 years of age or older. African American (AA) patients were diagnosed at significantly younger ages than were whites (P <0.001). In multivariate analysis, independent predictors of worse survival in AML were aged over 50 (hazard ratios [HRs]: 1.60, 2.15, 3.04, and 3.62 over the decade-cohorts, all P <0.001), AA race (HR: 1.27, P <0.001), being a former or current user of tobacco (HR: 1.13, P = 0.004 and HR: 1.28, P <0.001, respectively), residing in an area with the highest poverty level (HR: 1.15, P = 0.007), and being covered only by Medicaid (HR: 1.23, P = 0.014). No differences in outcomes were observed related to gender or ethnicity. Receipt of chemotherapy was strongly associated with improved survival (HR: 0.59, P <0.001). When only those patients who received and appeared to respond to treatment are included, AAs continued to demonstrate a worse outcome than Whites. Conclusions: AML disproportionately affects the elderly. AA patients and patients from poorer communities with AML have significantly worse survival. Interventions to provide earlier diagnosis in these patients as well as to improve overall outcomes are needed to address these disparities.

AB - Objectives: To determine how patient race, ethnicity, and degree of poverty affect treatment and survival for acute myeloid leukemia (AML). Methods: A linked database of the Florida cancer registry and State inpatient and outpatient hospital data for 1998-2002 was queried. Effects of demographic and treatment characteristics on survival were explored using univariate and multivariate analyses methods. Results: A total of 4659 patients with AML were identified. Over 50% of patients with AML were 70 years of age or older. African American (AA) patients were diagnosed at significantly younger ages than were whites (P <0.001). In multivariate analysis, independent predictors of worse survival in AML were aged over 50 (hazard ratios [HRs]: 1.60, 2.15, 3.04, and 3.62 over the decade-cohorts, all P <0.001), AA race (HR: 1.27, P <0.001), being a former or current user of tobacco (HR: 1.13, P = 0.004 and HR: 1.28, P <0.001, respectively), residing in an area with the highest poverty level (HR: 1.15, P = 0.007), and being covered only by Medicaid (HR: 1.23, P = 0.014). No differences in outcomes were observed related to gender or ethnicity. Receipt of chemotherapy was strongly associated with improved survival (HR: 0.59, P <0.001). When only those patients who received and appeared to respond to treatment are included, AAs continued to demonstrate a worse outcome than Whites. Conclusions: AML disproportionately affects the elderly. AA patients and patients from poorer communities with AML have significantly worse survival. Interventions to provide earlier diagnosis in these patients as well as to improve overall outcomes are needed to address these disparities.

KW - acute myeloid leukemia

KW - outcomes

KW - race

KW - socioeconomic status

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=79958272921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958272921&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3181dea934

DO - 10.1097/COC.0b013e3181dea934

M3 - Article

VL - 34

SP - 297

EP - 304

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -